CAJ | 학술논문

目的对比在不同的结果判定标准下胃食管结合部癌中人表皮生长因子受体2(HER2)的表达情况及其与临床病理学因素的关系.方法回顾性分析2009年1-12月间北京大学肿瘤医院外科收治的127例胃食管结合部癌患者的临床资料,并对手术标本进行免疫组织化学(免疫组化)染色.结果采用新的和传统的HER2免疫组化判定标准,HER2阳性表达率均为15.0%(19/127),强阳性率则分别为10.2%(13/127)和6.3%(8/127)(P=0.26).单因素分析显示,HER2表达与胃食管结合部癌肿瘤分化程度和Lauren分型有关;多因素分析则显示,肿瘤分化程度和TNM分期是影响HER2在胃食管结合部癌表达的独立因素(均P<0.05).结论新旧两种免疫组化判定标准下HER2的阳性率并无差异;HER2在胃食管结合部癌中的表达与临床病理特征关系密切.
목적 대비재불동적결과판정표준하위식관결합부암중인표피생장인자수체2(HER2)적표체정황급기여림상병이학인소적관계.방법 회고성분석2009년1-12월간북경대학종류의원외과수치적127례위식관결합부암환자적림상자료,병대수술표본진행면역조직화학(면역조화)염색.결과 채용신적화전통적HER2면역조화판정표준,HER2양성표체솔균위15.0%(19/127),강양성솔칙분별위10.2%(13/127)화6.3%(8/127)(P=0.26).단인소분석현시,HER2표체여위식관결합부암종류분화정도화Lauren분형유관;다인소분석칙현시,종류분화정도화TNM분기시영향HER2재위식관결합부암표체적독립인소(균P<0.05).결론 신구량충면역조화판정표준하HER2적양성솔병무차이;HER2재위식관결합부암중적표체여림상병리특정관계밀절.
Objective To compare the expression of human epidermal growth factor receptor 2 (HER2) under different scoring systems in gastroesophageal cancer and its relationship with clinicopathological features. Methods Clinicopathological data were retrospectively reviewed of 127 patients with gastroesophageal cancer between January and December 2009 in the Department of Surgery at the Cancer Hospital of Peking University. Tumor specimens were collected. The expression of HER2 protein was detected by immunohistochemistry. Results HER2 positive rate ((丌)/(卅)) in gastroesophageal cancer was 15.0% (19/127) with both new and traditional immunohistochemical scoring systems, while HER2 strong positive rate(卅) was 10.2%(13/127) and 6.3%(8/127), respectively (P=0.26).Univariate analysis showed that the expression rate of HER2 protein was associated with differentiation and Lauren classification of the tumor. Multivariable analysis showed that TNM staging and tumor differentiation were independently associated with the expression of HER2 protein (both P<0.05).Conclusions There is no change in HER2 positive rate in gastroesophageal cancer between the new and traditional immunohistochemical scoring systems. Expression of HER2 is associated with clinicopathological features in the gastroesophageal cancer.